CG
TVRD

Carmignac Gestion’s Tvardi Therapeutics TVRD Stock Holding History

Carmignac Gestion’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,059
Closed -$2.08M – 144
2021
Q2 		$2.08M Sell
4,059
-30,697
-88% -$19.5M 0.02% 115
2021
Q1 		$27.2M Sell
34,756
-16,673
-32% -$11.4M 0.31% 53
2020
Q4 		$28M Sell
51,429
-1,507
-3% -$790K 0.29% 54
2020
Q3 		$24.3M Sell
52,936
-4,429
-8% -$2.57M 0.29% 53
2020
Q2 		$35.3M Buy
57,365
+7,724
+16% +$4.27M 0.49% 43
2020
Q1 		$23.6M Buy
49,641
+24,403
+97% +$13.3M 0.4% 47
2019
Q4 		$14.6M Buy
25,238
+14,823
+142% +$10.4M 0.2% 48
2019
Q3 		$6.85M Sell
10,415
-7,717
-43% -$6.42M 0.09% 67
2019
Q2 		$14M Buy
18,132
+6,077
+50% +$4.27M 0.17% 51
2019
Q1 		$8.51M Buy
12,055
+994
+9% +$595K 0.1% 69
2018
Q4 		$5.18M Sell
11,061
-2,844
-20% -$1.83M 0.08% 77
2018
Q3 		$12M Sell
13,905
-2,880
-17% -$2.08M 0.1% 69
2018
Q2 		$11.6M Buy
+16,785
New +$8.53M 0.09% 70

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Carmignac Gestion's TVRD Position: Q3 2021 in Review

Carmignac Gestion sold out of Tvardi Therapeutics (TVRD) in Q3 2021, closing a stake of 4,059 shares — an estimated $2.08M sold.

Carmignac Gestion first reported a position in TVRD in Q2 2018 and held it in 13 quarters. The position peaked at $35.3M in Q2 2020. 169 funds tracked by Wall St. Rank hold TVRD as of Q3 2021.

  • Carmignac Gestion reported no remaining Tvardi Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Carmignac Gestion sold 4,059 Tvardi Therapeutics shares in Q3 2021, an estimated $2.08M.
  • Carmignac Gestion first reported a position in Tvardi Therapeutics in Q2 2018 and held it in 13 quarters.
  • Carmignac Gestion's Tvardi Therapeutics position peaked at $35.3M in Q2 2020.
  • 169 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2021.

Based on Carmignac Gestion's 13F filing for Q3 2021, filed 12 Nov 2021.